Wolverine Trading’s Carisma Therapeutics CARM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-10,100
Closed -$29.6K 4573
2023
Q4
$29.6K Hold
10,100
﹤0.01% 4344
2023
Q3
$42.7K Hold
10,100
﹤0.01% 4210
2023
Q2
$90.6K Hold
10,100
﹤0.01% 3804
2023
Q1
$31K Buy
+10,100
New +$96.2K ﹤0.01% 3936
2022
Q4
Sell
-2,875
Closed -$22K 4068
2022
Q3
$22K Buy
2,875
+335
+13% +$4.56K ﹤0.01% 4361
2022
Q2
$40K Buy
2,540
+100
+4% +$1.14K ﹤0.01% 4122
2022
Q1
$30K Buy
+2,440
New +$34.1K ﹤0.01% 5189
2021
Q4
Sell
-3,345
Closed -$51K 5954
2021
Q3
$51K Buy
+3,345
New +$161K ﹤0.01% 6013

Other funds holding CARM

Wolverine Trading's CARM Position: Q3 2022 in Review

Wolverine Trading sold out of Carisma Therapeutics (CARM) in Q3 2022, closing a stake of 838 shares — an estimated $11.4K sold.

Wolverine Trading first reported a position in CARM in Q3 2021 and held it in 2 quarters. The position peaked at $16K in Q3 2021. 68 funds tracked by Wall St. Rank hold CARM as of Q3 2022.

  • Wolverine Trading reported no remaining Carisma Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Wolverine Trading sold 838 Carisma Therapeutics shares in Q3 2022, an estimated $11.4K.
  • Wolverine Trading first reported a position in Carisma Therapeutics in Q3 2021 and held it in 2 quarters.
  • Wolverine Trading's Carisma Therapeutics position peaked at $16K in Q3 2021.
  • 68 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q3 2022.

Based on Wolverine Trading's 13F filing for Q3 2022, filed 14 Nov 2022.